Valuation: Kinarus Therapeutics Holding AG

Market Cap 47.17L 57.12L 50.92L 42.88L 80.47L 54Cr 81.79L 5.66Cr 2.22Cr 28Cr 2.14Cr 2.1Cr 90Cr P/E 2022
-0.23x
P/E 2023 -0.01x
Enterprise Value 47.08L 57.01L 50.82L 42.8L 80.32L 54Cr 81.64L 5.65Cr 2.22Cr 28Cr 2.14Cr 2.09Cr 90Cr EV / Sales 2022
43,18,722x
EV / Sales 2023 -
Free-Float
-
Yield 2022 *
-
Yield 2023 -
1 day+0.59%
Current month+6.03%
Current year+6.03%
3 years 0.9
Extreme 0.895999
33.15
5 years 0.9
Extreme 0.895999
230.27
10 years 0.9
Extreme 0.895999
230.27

Financials

2022 2023
Net sales 3.34 4.04 3.6 3.03 5.69 383.03 5.79 40.01 15.73 200.19 15.16 14.84 639.97 -
Net income -3.47Cr -4.21Cr -3.75Cr -3.16Cr -5.93Cr -398.78Cr -6.02Cr -42Cr -16Cr -208.43Cr -16Cr -15Cr -666.29Cr -4.94Cr -5.98Cr -5.33Cr -4.49Cr -8.42Cr -566.97Cr -8.56Cr -59Cr -23Cr -296.33Cr -22Cr -22Cr -947.29Cr
Net Debt 16.58L 20.08L 17.9L 15.08L 28.29L 19Cr 28.75L 1.99Cr 78.2L 9.95Cr 75.33L 73.76L 32Cr -9T -10.9T -9.72T -8.18T -15.36T -10.33L -15.61T -1L -42.45T -5L -40.89T -40.04T -17.27L
Projected Income Statement - Annual - Kinarus Therapeutics Holding AG
Logo Kinarus Therapeutics Holding AG
Kinarus Therapeutics Holding AG is a Switzerland-based Company that operates as a biopharmaceutical industry engaged in diseases treatment. The Company conducts its work within clinical-stage area and its activities include discovery, examination and development of medicines that are intended for the treatment of viral, respiratory, and ophthalmic diseases. Kinraus therapeutic drug is patent protected KIN001 which is a combination of pamapimod and pioglitazone. KIN0001 offers oral, long-term treatment of diseases with severe impact on the comfort of living.
Employees
-
Sector
-
Date Price Change
19/26/19 CHF 17.10 +0.59%
16/26/16 CHF 17.00 -2.58%
15/26/15 CHF 17.45 -4.90%
14/26/14 CHF 18.35 +1.10%
13/26/13 CHF 18.15 -4.47%
  1. Stock Market
  2. Stocks
  3. CURE Stock